u/source_or_silence

Is this a line they hold in regional stock or is it shipping from origin?

Which paper is that claim from, and was it in humans?

Yes — have the conversation before rather than after. That is the one piece of process advice this board can give.

the human evidence is thin and the rodent evidence is not

no clinical trial has established what these threads assert

Disagree — that is an obesity trial endpoint and this thread is about glycaemic control.

dose escalation in the trials was slow for a reason

Had the conversation with a clinician before stopping rather than after.

Disagreeing with this bit: stretching and reducing are different things and the post treats them as one.

Left up.

Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.

The mental model that finally made this click for me: there are two curves, and people watch the wrong one.

The first is exposure, which is set by the dose and smoothed by a week-long half-life. It changes when you change the dose and then settles over about a month. The second is body weight, which is exposure filtered through appetite, food, water, sleep, training and the scale itself, and which moves in steps rather than a line.

Almost every "it stopped working" post is somebody watching curve two over a fortnight and drawing conclusions about curve one. If the appetite effect is still there, exposure is fine. Wait the month.

Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.

The standing caveat, written out properly because it keeps getting compressed into a footnote.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Time in range told me far more than the average did. Two quarters with the same A1c looked completely different on the sensor.

That is a sensor value, not a plasma value, and the two are not interchangeable at that level of precision.

This. Hypoglycaemia risk in this class is driven mostly by the other agents in the regimen.

Yes — and the honest version is that most of the "it stopped working" posts turn out to be a normal fortnight of water weight.

the door shelf is the worst place in the fridge

Not convinced. You changed the dose and the week at the same time, so you cannot attribute the change to either.

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

Sceptical of the mechanism you are proposing. Gastric emptying slows, it does not stop, and the timings you describe do not follow from it.

That is a pause rather than a stop, and the plans for the two are not the same.

That was a hold rather than a loss, and it resolved. Updating rather than deleting.

the human evidence is thin and the rodent evidence is not

the phase 2 numbers were striking and they were also 48 weeks in a small population

Cosigning that going too fast is the most repeated regret on the whole site.

The evidence base, described honestly, which almost no summary of it does.

The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.

That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.

Not convinced. Hypoglycaemia risk from this class alone is low; the risk you are describing comes from the combination.

Small correction — the shop in that story has no independent testing on file at all, which is different from having a bad record.

Which lane, and had it been quoted at that transit time?

Kept a vial at room temperature for eleven days by accident. Tested it out of guilt. It was fine.

My stall was eleven weeks.

Right, and the timescale is the bit that keeps getting lost. Judge a step at a month, not at a weekend.

The appetite thing was the surprise. I expected to feel full. What I got was simply not thinking about food between meals.

the first four weeks are a tolerance check, not a weight-loss phase

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects.

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

research-use-only material is not approved for human use, full stop